Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases
- PMID: 19820689
- DOI: 10.1038/modpathol.2009.148
Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases
Abstract
Primary germ cell tumors of the central nervous system (CNS) sometimes pose diagnostic difficulty. In this study we analyzed the diagnostic utility of a novel marker, SALL4, in 77 such tumors (59 pure and 18 mixed) consisting of the following tumors/tumor components: 49 germinomas, 7 embryonal carcinomas, 27 yolk sac tumors, 3 choriocarcinomas, and 14 teratomas. We also stained SALL4 in 99 primary non-germ cell tumors to test SALL4 specificity. We compared SALL4 with OCT4 in all germ cell tumors and compared SALL4 with alpha-fetoprotein and glypican-3 in all yolk sac tumors. The staining was semiquantitatively scored as 0 (no staining), 1+ (<or=30%), 2+(31-60%), 3+ (61-90%), and 4+ (>90%). Strong SALL4 staining was observed in all 49 germinomas (4+ in 48, 3+ in 1), 7 embryonal carcinomas (all 4+), and 27 yolk sac tumors (1+ in 1, 2+ in 2, 3+ in 7, 4+ in 17). SALL4 staining, 1+ weak to focally strong, was observed in 2 of 3 choriocarcinomas (in mononucleated trophoblasts) and in 9 of 14 teratomas (in primitive neuroepithelium and teratomatous glands). All germinomas and embryonal carcinomas showed strong OCT4 staining (4+ in all except 1 germinoma with 3+), whereas other germ cell tumors were negative. Out of 27 yolk sac tumors, 26 showed positive alpha-fetoprotein staining (1+ in 9, 2+ in 7, 3+ in 5, and 4+ in 5). All yolk sac tumors showed positive glypican-3 staining (1+ in 6, 2+ in 6, 3+ in 7, and 4+ in 8). The mean percentage of yolk sac tumor cells stained was 84% with SALL4, 45% with alpha-fetoprotein, and 63% with glypican-3 (P<0.01). No non-germ cell tumors showed SALL4 staining. Our results indicate that SALL4 is a novel sensitive diagnostic marker for primary germ cell tumors of the CNS with high specificity. SALL4 is a more sensitive marker than alpha-fetoprotein and glypican-3 for yolk sac tumors.
Similar articles
-
Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors.Am J Surg Pathol. 2010 May;34(5):697-706. doi: 10.1097/PAS.0b013e3181db84aa. Am J Surg Pathol. 2010. PMID: 20410807
-
SALL4 is a novel diagnostic marker for testicular germ cell tumors.Am J Surg Pathol. 2009 Jul;33(7):1065-77. doi: 10.1097/PAS.0b013e3181a13eef. Am J Surg Pathol. 2009. PMID: 19390421
-
RNA-binding protein LIN28 is a marker for primary extragonadal germ cell tumors: an immunohistochemical study of 131 cases.Mod Pathol. 2011 Feb;24(2):288-96. doi: 10.1038/modpathol.2010.195. Epub 2010 Nov 5. Mod Pathol. 2011. PMID: 21057460
-
Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.Mod Pathol. 2005 Feb;18 Suppl 2:S61-79. doi: 10.1038/modpathol.3800310. Mod Pathol. 2005. PMID: 15761467 Review.
-
Discovery and diagnostic value of a novel oncofetal protein: glypican 3.Adv Anat Pathol. 2014 Nov;21(6):450-60. doi: 10.1097/PAP.0000000000000043. Adv Anat Pathol. 2014. PMID: 25299314 Review.
Cited by
-
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme.Front Surg. 2016 Apr 15;3:21. doi: 10.3389/fsurg.2016.00021. eCollection 2016. Front Surg. 2016. PMID: 27148537 Free PMC article. Review.
-
Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.J Immunol Res. 2014;2014:262385. doi: 10.1155/2014/262385. Epub 2014 Apr 17. J Immunol Res. 2014. PMID: 24860834 Free PMC article.
-
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.Cancer Res. 2021 Dec 1;81(23):6018-6028. doi: 10.1158/0008-5472.CAN-21-0030. Epub 2021 Sep 30. Cancer Res. 2021. PMID: 34593523 Free PMC article.
-
Teratoma of the Sellar Region: a Case Report.Endocr Pathol. 2017 Dec;28(4):315-319. doi: 10.1007/s12022-016-9465-0. Endocr Pathol. 2017. PMID: 28102527
-
HESRG: a novel biomarker for intracranial germinoma and embryonal carcinoma.J Neurooncol. 2012 Jan;106(2):251-9. doi: 10.1007/s11060-011-0673-7. Epub 2011 Aug 23. J Neurooncol. 2012. PMID: 21861197
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources